NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
16.00
+0.06 (0.38%)
At close: Jul 21, 2026, 4:00 PM EDT
15.90
-0.10 (-0.62%)
After-hours: Jul 21, 2026, 7:34 PM EDT
NovoCure Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, NovoCure stock has a consensus rating of "Buy" and an average price target of $24.88. The average 1-year stock price forecast is 55.50% higher than the current stock price, while the lowest is $17 (+6.25%) and the highest is $46 (+187.50%).
Price Target: $24.88 (+55.50%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for NovoCure stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Maintains $17 | Hold | Maintains | $17 | +6.25% | Jul 13, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $46 | Buy | Maintains | $46 | +187.50% | Jul 13, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Hold Maintains $18 | Hold | Maintains | $18 | +12.50% | Jun 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $27 | Buy | Maintains | $27 | +68.75% | May 26, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $14 → $17 | Hold | Reiterates | $14 → $17 | +6.25% | May 4, 2026 |
Financial Forecast
Revenue This Year
708.03M
from 655.35M
Increased by 8.04%
Revenue Next Year
790.22M
from 708.03M
Increased by 11.61%
EPS This Year
-1.59
from -1.22
EPS Next Year
-1.06
from -1.59
EPS and Forward PE are based on non-GAAP adjusted numbers.